Description
PF-07248144 is an experimental drug currently being studied by Pfizer in clinical trials for advanced or metastatic solid tumors, including colorectal cancer. It is being investigated in Phase 2 trials to determine the best dose and how it works in combination with other cancer treatments. The trials are designed to find the maximum dose that can be tolerated (MTD) and the recommended dose for expansion (RDE). PF-07248144 is being tested both by itself and in combination with other drugs like fulvestrant, palbociclib, letrozole, PF-07220060, vepdegestrant, and PF-07850327. These trials are actively recruiting patients. The goal is to see if PF-07248144 can effectively treat these cancers.
Mechanism of Action
PF-07248144 is being studied in clinical trials. The specific way it works (its mechanism of action) is being investigated as part of these trials. It is being tested alone and in combination with other drugs to see how it affects tumor growth and progression in patients with advanced solid tumors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.